Jingxin Pharmaceutical: It has not cooperated with Shiono Pharmaceutical and Pfizer on COVID-19 drugs

On March 27, Financial Union News Agency, Jingxin Pharmaceutical announced the stock price change announcement, noting that there are rumors on the Internet about “the company has trifluorobenzoyl chloride novel coronavirus drug API”, “Jingxin Pharmaceutical has both shionyeyi/Pfizer novel coronavirus drug key intermediates only one target”.The company clarified that the company’s API drugs are mainly quinolones, statins, and neurotic drugs. At present, the company and its subsidiaries have not carried out COVID-19 drug cooperation with Shionoyi Pharmaceutical And Pfizer.

Leave a Reply

Your email address will not be published.